Oral JAK inhibitor baricitinib effective in JIA.
作者信息
McHugh Jessica
机构信息
Nature Reviews Rheumatology, .
出版信息
Nat Rev Rheumatol. 2023 Sep;19(9):539. doi: 10.1038/s41584-023-01019-y.
PMID:37532782
Abstract
摘要
相似文献
1
Oral JAK inhibitor baricitinib effective in JIA.口服JAK抑制剂巴瑞替尼对幼年特发性关节炎有效。
Nat Rev Rheumatol. 2023 Sep;19(9):539. doi: 10.1038/s41584-023-01019-y.
2
The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.JAK1/2 抑制剂巴瑞替尼抑制嗜酸性粒细胞效应功能，并限制变应原诱导的气道嗜酸性粒细胞增多。
Biochem Pharmacol. 2021 Oct;192:114690. doi: 10.1016/j.bcp.2021.114690. Epub 2021 Jul 16.
3
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.巴利昔替尼：治疗中重度特应性皮炎的潜力。
Expert Opin Investig Drugs. 2020 Oct;29(10):1089-1098. doi: 10.1080/13543784.2020.1800639. Epub 2020 Aug 14.
4
Repigmentation of vitiligo with oral baricitinib.口服巴瑞替尼治疗白癜风的再色素沉着
Australas J Dermatol. 2020 Nov;61(4):374-376. doi: 10.1111/ajd.13348. Epub 2020 Jun 3.
5
Effective treatment of oral lichen planus with the JAK inhibitor baricitinib.使用JAK抑制剂巴瑞替尼有效治疗口腔扁平苔藓。
Australas J Dermatol. 2022 May;63(2):276-277. doi: 10.1111/ajd.13811. Epub 2022 Feb 25.
6
Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.Janus 激酶抑制剂芦可替尼和巴瑞替尼可损害糖蛋白-VI 介导的血小板功能。
Platelets. 2022 Apr 3;33(3):404-415. doi: 10.1080/09537104.2021.1934665. Epub 2021 Jun 7.
7
Successful treatment of alopecia areata-associated trachyonychia with baricitinib.用巴瑞替尼成功治疗斑秃相关的毛周角化病。
Int J Dermatol. 2024 Aug;63(8):1089-1090. doi: 10.1111/ijd.17137. Epub 2024 Mar 21.
8
Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.巴瑞替尼成功用于治疗难治性类风湿关节炎相关的Sweet综合征。
Clin Exp Dermatol. 2021 Oct;46(7):1330-1332. doi: 10.1111/ced.14712. Epub 2021 Jun 4.
9
Baricitinib in Alopecia Areata.巴瑞替尼治疗斑秃
N Engl J Med. 2022 May 5;386(18):1751-1752. doi: 10.1056/NEJMe2203440.
10
Oral Baricitinib Restores Hair Loss in Alopecia Areata.口服巴瑞替尼可恢复斑秃患者的脱发问题。
JAMA. 2022 Jun 28;327(24):2386. doi: 10.1001/jama.2022.10378.
本文引用的文献
1
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.巴瑞替尼治疗幼年特发性关节炎：一项国际、3 期、随机、双盲、安慰剂对照、停药、疗效和安全性试验。
Lancet. 2023 Aug 12;402(10401):555-570. doi: 10.1016/S0140-6736(23)00921-2. Epub 2023 Jul 6.
Zotero 插件